×
Overview
This workshop will be conducted in Japanese Language only.
View the Program in Japanese
Program Committee
-
Kentaro Kogushi, PHD Head of Clinical Development Neurology-Psychiatry, Japan Development
AbbVie GK, Japan -
Toshihiko Aranishi, PHD Research Scientist, Health Outcomes/Health Technology Assessment
Eli Lilly Japan K.K, Japan -
Mariko Hirozane, PHD Associate director, Policy intelligence department, Integrated Market Access Div
Janssen Pharmaceutical K.K. , Japan -
Shinya Ohno, PHD, MPH Director, HTA Strategy Professional
Chugai Pharmaceutical Co., Ltd, Japan -
Akihito Uda, MPH Health Economics & Outcome Reserch, Value & Access Division
Novartis Pharma K.K., Japan -
Hisashi Urushihara, DrPH Professor, Faculty of Pharmacy, Department of Pharmacy
Keio University, Japan -
Kentaro Yamato, RPH Head of HEOR/RWE, Medical Affairs
Otsuka Pharmaceutical Co., Ltd., Japan -
Keisuke Yoshihara, PHD, MSC HEOR Research Associate
Bayer Yakuhin, Ltd., Japan -
Manami Yoshida, DVM Associate Director, Medical Affairs – HIV & COVID-19
Gilead Sciences K.K., Japan -
Shinzo Hiroi, PHD, MPH, RPH, PMP Senior Director, Project Management, IDC ICO Real World Solutions
ICON Clinical Research GK, Japan -
Yuta Kasai Japan-Asia Clinical Development 2
Astellas Pharma Inc., Japan -
Akiko Nishioka Clinical Project Manager
Novartis Pharma K.K., Japan
Have an account?